Login/Register

Nanobody based Trispecific Antibody of T cell Engager with Dual ICP Targets, Nb-TriTE (SOA101)

Taiwan
Introduction
Tumor microenvironment (TME) of solid tumors is more complicated compared to hematological tumors . Many current treatment modalities, including immune checkpoint inhibitors (ICIs), have demonstrated limited efficacy with only 20-30% of patients benefiting due to high rates of drug resistance. Shine-On has developed a next-generation nano-based antibody drug against cancer, i.e., "Nanobody-based Trispecific T Cell Engager, Nb-TriTE (SOA101)”. SOA101 is designed with three specific antibodies, two of which are against immune checkpoints on tumor cells (PD-L1 and HLA-G) for reduction of drug resistance to ICIs by change on tumor microenvironment. The third antibody can bind to CD3 of T cells, which allows SOA101 to locally activate T cells and enhance T cell mediated tumor cytotoxicity. Moreover, nanobody-based VHHs has a high affinity to the targets, which increases the specificity, reduces side effects, and improves the patient safety of SOA101.
SOA101 is a broad spectrum anticancer drug expected to apply for the treatment of lung cancer, oral cancer, breast cancer, ovarian cancer and other solid tumors. According to a report from WHO, lung CA is the second most common cancer in the world. In the Asia-Pacific region, non-small cell lung cancer (NSCLC), accounting for 80-85% of lung cancer, is usually in an advanced stage when diagnosed; the 5-year survival rate is very low, even with target therapy, ICIs and chemotherapy treatment, 15.1% in stage III and 6% in stage IV. Late stage NSCLC is an unmet medical need and effective new drug development is an emergent. The product is expected to be at Clinical Phase regulated by US FDA in 2024.
Features / strengths
The distinctive advantages of SOA101 are as follows:
1. Leading in Asia: We are at the forefront in Asia, offering the unique "triple-specific antibody" that targets dual immune checkpoints on cancer cells.
2. Innovative Nanobody based VHHs: Our innovative nano-targeting approach allows for the effective penetration of the tumor environment by binding to antigenic regions, thereby enhancing drug efficacy and safety.
3. PD-L1/HLA-G Dual Immune Checkpoint Antibodies: The dual immune checkpoint antibodies, targeting PD-L1 and HLA-G, work in synergy to overcome immune evasion by cancer cells. This leads to treatment effectiveness improvement and a reduction in the occurrence of drug resistance.
4. Highly Specific HLA-G Cancer Target: HLA-G is a highly specific cancer target, and our Anti-HLA-G therapy can modulate various immune cells.
5. Enhanced Localized Anticancer Effect: The fusion of the Fc segment with the specific targeting moiety enhances the localized anticancer effects, minimizes drug rejection, and extends the half-life of the drug.
6. Broad-Spectrum Anticancer Drug: Our novel anticancer drug offers broad-spectrum treatment, encompassing but not limited to lung cancer, oral cancer, breast cancer, ovarian cancer, and other solid tumors.
Specification in detail
capacity
NA
concentration
NA

Information
Introduction
Tumor microenvironment (TME) of solid tumors is more complicated compared to hematological tumors . Many current treatment modalities, including immune checkpoint inhibitors (ICIs), have demonstrated limited efficacy with only 20-30% of patients benefiting due to high rates of drug resistance. Shine-On has developed a next-generation nano-based antibody drug against cancer, i.e., "Nanobody-based Trispecific T Cell Engager, Nb-TriTE (SOA101)”. SOA101 is designed with three specific antibodies, two of which are against immune checkpoints on tumor cells (PD-L1 and HLA-G) for reduction of drug resistance to ICIs by change on tumor microenvironment. The third antibody can bind to CD3 of T cells, which allows SOA101 to locally activate T cells and enhance T cell mediated tumor cytotoxicity. Moreover, nanobody-based VHHs has a high affinity to the targets, which increases the specificity, reduces side effects, and improves the patient safety of SOA101.
SOA101 is a broad spectrum anticancer drug expected to apply for the treatment of lung cancer, oral cancer, breast cancer, ovarian cancer and other solid tumors. According to a report from WHO, lung CA is the second most common cancer in the world. In the Asia-Pacific region, non-small cell lung cancer (NSCLC), accounting for 80-85% of lung cancer, is usually in an advanced stage when diagnosed; the 5-year survival rate is very low, even with target therapy, ICIs and chemotherapy treatment, 15.1% in stage III and 6% in stage IV. Late stage NSCLC is an unmet medical need and effective new drug development is an emergent. The product is expected to be at Clinical Phase regulated by US FDA in 2024.
Features / strengths
The distinctive advantages of SOA101 are as follows:
1. Leading in Asia: We are at the forefront in Asia, offering the unique "triple-specific antibody" that targets dual immune checkpoints on cancer cells.
2. Innovative Nanobody based VHHs: Our innovative nano-targeting approach allows for the effective penetration of the tumor environment by binding to antigenic regions, thereby enhancing drug efficacy and safety.
3. PD-L1/HLA-G Dual Immune Checkpoint Antibodies: The dual immune checkpoint antibodies, targeting PD-L1 and HLA-G, work in synergy to overcome immune evasion by cancer cells. This leads to treatment effectiveness improvement and a reduction in the occurrence of drug resistance.
4. Highly Specific HLA-G Cancer Target: HLA-G is a highly specific cancer target, and our Anti-HLA-G therapy can modulate various immune cells.
5. Enhanced Localized Anticancer Effect: The fusion of the Fc segment with the specific targeting moiety enhances the localized anticancer effects, minimizes drug rejection, and extends the half-life of the drug.
6. Broad-Spectrum Anticancer Drug: Our novel anticancer drug offers broad-spectrum treatment, encompassing but not limited to lung cancer, oral cancer, breast cancer, ovarian cancer, and other solid tumors.
Specification in detail
capacity
NA
concentration
NA

Nanobody based Trispecific Antibody of T cell Engager with Dual ICP Targets, Nb-TriTE (SOA101)

Taiwan
Shine-On BioMedical Co., Ltd Other products
Recommended